Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies
Status:
Completed
Trial end date:
2019-11-13
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to confirm the safety of KamRAB (Human Rabies
Immunoglobulin) in children ages 0 months to <17 years, when administered as part of
post-Rabies Exposure Prophylaxis (PEP).